Carvedilol therapy increased ejection fraction by 7 percentage points (from 25% to 32%, P<0.0001) at 6 months, driven primarily by heart rate reduction and increased contractility.
Observational (n=29)
What are the relative contributions of heart rate reduction, positive inotropism, and afterload reduction to improvements in ejection fraction with carvedilol in patients with heart failure?
Improvements in ejection fraction with carvedilol in heart failure are multifactorial, primarily driven by heart rate reduction, followed by increased contractility and afterload reduction.
Tasa de eventos absoluta: 32% vs 25%
valor p: p=<0.0001
BACKGROUND: Reductions in heart rate (HR) with beta-blocker therapy have been associated with improvements in ejection fraction (EF). However, the relative contributions of HR reduction, positive inotropism, afterload reduction, and reverse remodeling to improvements in EF are unknown. METHODS AND RESULTS: Twenty-nine patients (63+/-12 years old) with New York Heart Association class II-III heart failure underwent serial measurements of left ventricular volumes using 3-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6, and 12 months after initiation of carvedilol. From these parameters, left ventricular contractility (indexed by the end-systolic pressure-volume ratio), total peripheral resistance, and effective arterial elastance (E(a)) were derived. Overall, EF increased by 7-percentage points after 6 months of therapy (from 25+/-9 to 32+/-9, P<0.0001). This change was due to an increase in stroke volume (P<0.001) with no significant change in end-diastolic volume (P=0.15). The EF change correlated with increased contractility, decreased HR and decreased total peripheral resistance (P<0.003 in each case). In those patients whose EF increased at least 5 points, approximately 60% of the increase was due to HR reduction, approximately 30% was due to increased contractility, and <20% was due to the decrease in total peripheral resistance. CONCLUSIONS: Decreased HR, improved chamber contractility and afterload reduction each contributed significantly to improved EF with carvedilol.
Maurer et al. (Wed,) conducted a observational in New York Heart Association class II-III heart failure (n=29). Carvedilol vs. Baseline was evaluated on Change in ejection fraction at 6 months (p=<0.0001). Carvedilol therapy increased ejection fraction by 7 percentage points (from 25% to 32%, P<0.0001) at 6 months, driven primarily by heart rate reduction and increased contractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: